Immunovant is a New York-based biopharmaceutical company that develops and commercializes therapies for the treatment of autoimmune diseases.
Business Model:
Revenue: $0
Employees: 51-200
Address: 320 W 37th Street
City: New York
State: NY
Zip: 10018
Country: US
Immunovant is a New York-based biopharmaceutical company that develops and commercializes therapies for the treatment of autoimmune diseases.
Contact Phone:
Contact Email:
Listed Exchange:
NASDAQ
IPO Date:
4/14/2020
Ticker Symbol:
IMVT
IPO Price:
$14.5/share
Opened: -/share
EBITDA | - |
Total Cash | - |
Total Debt | - |
Total Revenue | - |
Total Profit (Gross) | - |
PE Ratio | - |
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 10/2022 | Post-IPO Equity | 6 | $75M |
TCG Crossover Logos Capital Frazier Life Sciences Deep Track Capital Commodore Capital BVF Partners |
10/2022 | Post-IPO Equity | $75M | 8/2021 | Corporate Round | 2 | $200M |
Frazier Healthcare Partners Roivant Sciences Frazier Healthcare Partners Roivant Sciences |
10/2019 | Equity | $35M |
RTW Investments BVF Partners Roivant Sciences Ltd |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|